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BACKGROUND: In the US, over 1 million Asian Amer-
icans are estimated to be living with chronic hepatitis B
(CHB). Research has shown low awareness of CHB and
different attitudes towards its treatment among the
diverse ethnicities of Asian Americans.
OBJECTIVE: This study aimed to understand the
perceptions and attitudes of CHB treatment among
Asian Americans diagnosed with CHB who were either
treatment-naïve or being treated for CHB with oral
antivirals, and to understand the relative importance
of different clinical and economic attributes of oral
antivirals that affect CHB treatment decisions and
choices.
DESIGN: Face-to-face structured survey administered
to participants at central research facilities by inter-
viewers of each participating ethnicity.
PARTICIPANTS: CHB patients from Chinese, Korean,
and Vietnamese communities of New York metropolitan,
San Francisco/Bay, and Los Angeles/Orange County
areas.
MAIN MEASURES: A ‘conjoint’ exercise (discrete choice
model) assessed the relative impact of treatment attri-
butes on treatment choice. Implicit “trade-off” decisions
made by respondents were estimated using a hierar-
chical Bayesian model.
KEY RESULTS: Among 252 participants, 36 % were
Chinese, 34 % Vietnamese, and 31 % Korean; 56 %
were treatment-naïve and 44 % were being treated with
an oral antiviral for CHB. The majority (88 %) believed
that, if left untreated, CHB can lead to serious liver
damage; 72 % believed there are effective prescription
medications to treat CHB; and 39 % showed reluctance
to be on long-term therapy for CHB because of concerns
over side effects. Long-term risk of kidney damage was
given the highest relative importance (38 %) when
choosing CHB treatment, followed by medication cost
(23.4 %), long-term risk of bone thinning (18 %), long-
term efficacy (9 %), time on US market (6.8 %), and
number of patients treated globally (4.9 %). Results
were consistent across ethnicities.
CONCLUSIONS: Patients need access to improved
education regarding CHB disease progression, its man-
agement, disease outcomes, and the importance of
long-term treatment of the disease.
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INTRODUCTION
Chronic hepatitis B (CHB) remains a significant global
health burden, despite widespread hepatitis B virus (HBV)
vaccination programs. In the US, estimates suggest that
more than 2 million people are living with CHB1,2 and that
the clinical sequelae of untreated CHB, such as cirrhosis,
hepatic decompensation, and hepatocellular carcinoma
(HCC), contribute to up to 4,000 deaths per year.1,2
Effective antiviral therapy can reduce progression to
cirrhosis and minimize the risk of HCC;3–5 however, in
the US, HBV antiviral treatment is prescribed to fewer than
50,000 people per year.6 Possible reasons for the apparently
low treatment rate include insufficient screening and
diagnosis and a need for better education and referral,
particularly for disproportionately infected populations.
Approximately half the cases of CHB in the US are among
Asian American individuals who have migrated from areas
with a high prevalence of HBV infection.1–3 The Asian
American population is a rapidly growing and diverse
community, estimated to increase from 4.8 % of the US
population in 2010 to 9 % in 2050.7,8 Asian American
individuals generally acquire HBV infection perinatally or
early in life, and have a high risk of progression to CHB
and subsequent long-term complications including HCC.
Early diagnosis and appropriate, effective treatment are
therefore of particular importance in this population, and it
is desirable that primary care physicians are aware of what
key factors influence the choices that Asian American
patients make and barriers that may prevent them from
seeking treatment.
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Previous research has shown variable awareness of CHB
among the diverse ethnicities of the Asian American
population and different attitudes towards CHB treatment
for Asian American patients among primary care pro-
viders.3,9,10 Several studies have indicated that lack of
knowledge about HBV transmission and its consequences
leads to low levels of vaccination and screening. A number
of initiatives have been implemented to raise the uptake of
vaccination and screening in the Asian American popula-
tion, with some success.11–14 To our knowledge, no studies
have specifically evaluated the level of awareness among
Asian American individuals of current potent antiviral
therapies available for the treatment of CHB.
This study aimed to evaluate perceptions and attitudes
about CHB treatments among Asian American individuals
diagnosed with CHB, and to assess factors affecting
treatment decision and choice.
METHODS
The primary objective of this study was to determine, among
Asian Americans diagnosed with CHB (treatment-naïve or
already being treated for CHBwith oral antivirals), the relative
importance of different attributes of oral antivirals in making
treatment decisions and product choices. A key secondary
objective was to assess general attitudes toward CHB
treatment among Asian Americans diagnosed with CHB.
Participants
During November and December of 2011, participants were
recruited from Chinese, Korean and Vietnamese communi-
ties, since these represent the Asian American populations
with the highest prevalence of CHB.3 Sources included GC
Global’s panels; grass-root recruitment efforts at local
community centers; health centers, doctors’ offices and
clinics in the local Chinese, Korean and Vietnamese
communities; and networking and referrals from families
and friends of CHB patients, non-medical staff, community
workers and social workers who work with or know of
CHB patients in these communities. Participants were
screened to meet key target criteria: 18–65 years old;
Chinese, Korean, or Vietnamese ethnicity; with a doctor’s
diagnosis of CHB at least 6 months previously; on current
antiviral treatment for CHB treatment (Treated) or naïve to
CHB antiviral treatment (Treatment-naïve); and with no
participation in CHB studies in the last 6 months. Quotas
were applied to achieve a good balance in the sample in
terms of age, gender, treatment status, ethnicity, and region
of the US. Screening included criteria designed to ensure
that respondents had at least a minimum level of concern
about their CHB condition: must have CHB check-ups with
their doctor at least every 1–2 years (or more often); must
not be totally opposed to the idea of taking Western
medicines to treat CHB (“not receptive” and “not at all
receptive” responders were screened out).
Survey
Study data were collected during December 2011 using a
structured online survey, including the following sections:
demographic data, treatment status, a ‘Conjoint’ exercise
(using a discrete choice model), cost sensitivity, and treatment
attitudes. The survey was translated into Chinese, Korean, and
Vietnamese, and was administered at central research facilities
by trained interviewers of each participating ethnicity who
entered participants’ responses into the online database.
Participants were given the option of conducting the interview
in their native Asian language or in English.
Conjoint Exercise
To assess what attributes of oral antivirals have the greatest
influence on the treatment choices that participants make, a
conjoint exercise was carried out. The conjoint exercise used a
discrete choice model15 that required participants to choose
between pairs of hypothetical products characterized by a set of
six product attributes: long-term efficacy, 5-year risk of thinning
of bones, 5-year risk of kidney disease, weight of evidence
(number of patients treated), weight of evidence (number of
years in the market) and cost, as detailed in Table 1. The chosen
Table 1. Attribute Definitions Used in the Discrete Choice Model
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characteristics are derived from previous quantitative and
qualitative research studies as being likely to have some
relevance as consideration factors for Asian patients (GC
Global data on file). For each hypothetical product, each of
the attributes could be set at one of three or four possible levels,
reflecting the ranges reported in the literature. For each of the
attributes, one or two of the possible levels accurately reflected
levels reported for one or more of the antiviral therapies
available at the time of the survey,16–20 while the other levels
were outliers. Such a broad range of levels improved the
measurement of trade-offs, since the difference across the range
was big enough to make participants’ choices clear. A total of
64 product comparison scenarios (comparisons between two
hypothetical products) were used. These scenarios were
selected using an orthogonal design and were divided into eight
blocks, each with eight different scenarios using a balanced
design, so that within each block, all respondents saw all levels
of each attribute proportionally (Online Supplementary Figure
S1). No two products or scenarios used in the design were
exactly alike. In each scenario, participants were asked to
choose between the two hypothetical products (coded with
letters), with the assumption that both were approved and
deemed suitable for them by their physician. Each participant
was presented with one block of eight scenarios. Each block
was seen by an equal number of Treated and Treatment-naïve
participants. Care was taken to ensure that the attributes were
described in patient-friendly terminology. Interviewers made
sure that each participant fully understood both the terminology
and the requirements of the conjoint exercise before starting it.
Statistical processing of the implicit “trade-off” decisions
made by participants in each of the product comparison
scenarios used hierarchical Bayesian methodology. This
method enables the use of a limited number of scenarios
with limited attributes, and thus avoids potential survey
fatigue, which can reduce the reliability of the data. To
capture sample variation among the participants, data
analysis was conducted using the statistical software
“RJAGS 3.2” (www.cran.r-project.org) to estimate individ-
ual level parameters using Markov Chain Monte Carlo
(MCMC). The simulations use these individual level
parameters to compute share at an individual basis, which
is added across to get the aggregate share. Two main types
of information were generated: the relative importance of
attributes, which describes the weight or importance that
each attribute has in determining the overall appeal of a
product, with the total relative importance of all attributes
adding up to 100 %; and the relative preference, providing
an indication of the percent of participants who would be
likely to choose a particular product, based on its
configuration of attribute levels. A sensitivity analysis was
conducted to assess the impact on the relative preference for
a product caused by changes in the levels of its individual
attributes. This analysis was initiated from a “base case”
product configuration, with one attribute flexed at a time,
while holding all others constant at base case levels.
Cost Sensitivity Analysis
Following the conjoint exercise, all respondents were
shown a product configuration that matched the attribute
levels of a hypothetical optimal product, and were told to
assume that their physician had recommended that they start
taking this medication. They were then asked to state the
likelihood that they would take the medication, at seven
different out-of-pocket monthly costs ($0, $50, $100, $150,
$200, $250, and $500), presented in random order.
Likelihood was scored on a 5-point scale: 1 = definitely
not, 2 = quite unlikely, 3 = may or may not, 4 = quite likely,
5 = definitely. They were also asked to specify the
maximum acceptable monthly cost for this medication.
Cost-sensitivity analyses were performed using a linear
model, with reported beta estimates.
Treatment Attitudes
A battery of statements about treatment attitudes was included
in the survey to assess the attitudinal profile of the sample and
to provide ongoing longitudinal data in this area. Responses
scored the statements on a scale of 1 to 5 (1 = completely
disagree, 2 = mostly disagree, 3 = somewhat agree, 4 = mostly
agree, 5 = completely agree). Differences in responses
between Treated and Treatment-naïve patients were assessed
for statistical significance using a two-tailed T-test (signifi-
cance level p=0.05) using the SPSS software.
RESULTS
Sample Composition
A total of 252 participants completed the survey. The
participant sample provided a balance across demographic
subgroups (Table 2). The majority of participants (141,
[56 %]) were Treatment-naïve, with 111 (44 %) on current
CHB antiviral treatment, mostly with entecavir, tenofovir,
or adefovir, reflecting the current US treatment pattern. The
median time since diagnosis was 4 years among patients on
current antiviral treatment and 5 years among Treatment-
naïve patients. Around 60 % of participants had been
diagnosed with CHB in the last 5 years.
Conjoint Exercise (Discrete Choice Model)
The relative impact of product attributes on product choice
in the discrete choice model for the total group is shown in
Table 3. The attributes that had the greatest impact on
product choice were the risk of kidney damage (38 %) and
out-of-pocket cost (23 %), between them accounting for
over 60 % of total relative importance. The risk of bone
thinning was also an important factor, accounting for 18 %
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of total importance. Long-term efficacy, within the range
used in this study (71–92 % efficacy), was of lower relative
importance (9 % of total). ‘Weight of evidence’ factors had
relatively little importance in selection decisions: time in the
US market (7 % of total) and number of patients worldwide
(5 % of total).
The relative importance of attributes was highly consistent
across ethnicities (Table 3). Results were also broadly
consistent by treatment status (Table 3), except that Treated
participants appeared to be more sensitive to out-of-pocket cost
than Treatment-naïve participants. In addition, Treatment-naïve
participants ascribed greater importance than Treated partici-
pants to the risk of bone thinning and to long-term efficacy.
The results of the sensitivity analysis assessing the
impact of changing individual attributes on the preference
for two hypothetical products ‘A’ and ‘B’ are shown in
Figure 1. Changes to the risk of kidney damage had the
highest impact on overall product preference, with a large
range in relative preference from the “best case” (< 1 % 5-
year risk) to “worst case” (20 % 5-year risk) levels. Relative
preference dropped sharply when the long-term risk started
to exceed 10 %. Changes in the risk of bone thinning and in
out-of-pocket cost both had quite a high impact on relative
preference over the range assessed. Progressive increases in
the risk of bone thinning reduced relative preference at a
fairly rapid rate. The influence of out-of-pocket cost on
product preference was more noticeable as the cost
exceeded $100/month, suggesting this to be an important
psychological barrier. The change in relative preference
between “best case” and “worst case” levels was fairly
small in the case of long-term efficacy, time in the US
market, and number of patients worldwide.
Cost Sensitivity
The results of the cost-sensitivity analysis are shown in
Figure 2. Between $100 and $250, a 10 % drop in projected
willingness to pay for treatment was seen for each $25 cost
increase among Treated patients and for each $35 cost increase
for Treatment-naïve patients. Overall, participants indicated an
apparent willingness to pay monthly out-of-pocket costs in
excess of the actual levels reported by those who were taking
CHB treatment at the time of the survey. When shown the
seven different cost levels for Product ‘A’, approximately
75 % of participants indicated a willingness to pay $100/
month, with around 50 % willing to pay $150/month. When
asked to specify a maximum acceptable cost, the mean
response among all participants was $138/month (median
$100/month). In contrast, around 80 % of Treated patients
indicated that theywere currently spending ≤ $50 per month in
out-of-pocket costs (mean $42/month, median $15/month).
Treatment Attitudes
The majority of patients (88 % overall) acknowledged the
seriousness of CHB and support the need for antiviral medication
Table 2. Participant Demographics and Treatment Status (N=252)
Classification n (%)
Gender Male 128 (51)
Female 124 (49)


















Education Less than high school 12 (5)









Full-time employed 111 (44)






















> $100,000 per year 16 (6)
















Once per month 7 (6) 0
Every 3 months 45 (41)† 13 (9)
Every 6 months 45 (41) 60 (43)
Once per year 8 (7) 51 (36)†
Once every 1–2 years 6 (5) 17 (12)†
Medical
insurance
Total with insurance 87 (78) 108 (77)
Employer plan 34 (39) 59 (55)†
Family Health Plus‡ 19 (22)† 10 (9)
Other self-paid 8 (9) 16 (15)
Medicare§ 9 (10) 12 (11)
Medicaid∥ 12 (14) 7 (6)
Unknown 5 (6) 4 (4)
NA not applicable
*Mean length of residence in USA 16 years
†Significantly higher than the other group (p<0.05)
‡Family Health Plus is a US public health insurance program for
adults who have income too high to qualify for Medicaid
§Medicare is a social insurance program administered by the US
government for Americans over 65 years of age and younger persons
with disabilities, end-stage renal disease or Lou Gehrig’s disease
∥Medicaid is the US means-tested health program for persons with
low income
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(Fig. 3). Overall, 72 % believed that there are effective
prescription medications to treat CHB. A substantial minority
(particularly among Treatment-naïve patients) showed reluctance
to be on long-term therapy for CHB, because of concerns over
side effects. A similar proportion believed that a change in
lifestyle and diet would be sufficient to manage their CHB.
DISCUSSION
The study findings provide important insights about the
perceptions and attitudes of CHB medications among Asian
Americans already diagnosed with CHB or on treatment for
CHB. The assessment of treatment attitudes showed that the
great majority of participants (> 70 %), both Treated and
Treatment-naïve, acknowledged the seriousness of CHB,
supported the need for effective antiviral treatment, and
were aware of available treatments. An earlier survey
carried out in 2007 among Asian American individuals
from Chinese, Korean, and Vietnamese communities,
randomly selected from telephone directories, reported a
slightly lower awareness of available treatments (around
50 %).10 The reduced awareness in the earlier study can be
explained by the inclusion of participants without CHB.
Increased awareness in our 2011 study may also reflect
increased experience with potent antiviral treatments, the
impact of updated treatment guidelines (issued in 2009),5
and the impact of targeted public health campaigns
launched since 2007.21 Despite this increased awareness
of treatments, a substantial minority of participants (close to
50 % among the Treatment-naïve) was reluctant to take
long-term medication because of concerns about potential
side effects, and almost as many believed that lifestyle and
diet would be sufficient to manage their disease. These
results are consistent with the results of the 2007 study, in
which the majority of participants expressed concern about
possible treatment side effects (61 %) and almost 20 %
believed that herbal medicines offered a better treatment
alternative.10 The high level of belief that diet and lifestyle
can be used to manage disease may have a cultural
influence. Many Asian cultures place high value on herbal
medicines and traditional remedies, and cultural barriers
have also been cited as hindering screening in this
population.10
Concerns about potential side effects were also apparent
in the results of the discrete choice model. Attributes
pertaining to the long-term risk of side effects were shown
to have substantially the greatest impact on product choice.
Considering the chronic nature of the disease, concerns over
long-term side effects are not surprising. However, there is a
large body of evidence supporting the safety and tolerability
of long-term antiviral therapy in both global and Asian
CHB populations.22–25 It is important that Asian Americans
are educated about these data, and about the significant
impact that effective treatment can have on disease
progression. The role of managing physicians will be key
in providing such education. Currently, physicians may tend
to focus more on the long-term efficacy of treatments rather
than on patients’ concerns over side effects; however, it is
important that physicians managing Asian American pa-
tients with CHB are sensitive to the high level of concern
over side effects, and are able to provide a balanced
explanation of the relative risks of disease progression over
those of potential adverse events.
The long-term risk of kidney damage had a large impact
on treatment choice. Nephrotoxicity has been reported as a
potential concern with adefovir and tenofovir (in the latter
case specifically for patients receiving tenofovir for HIV
infection).16 So far, the effects of these agents on renal
function in patients with HBV infection have proved to be
mild.26 Nevertheless, prescribing information for tenofovir
recommends regular monitoring of creatinine clearance in
all patients,16 and this may present a barrier to uptake
among patients concerned about side effects.
Out-of-pocket cost also carried considerable weight.
Concerns about the cost of treatment have previously been
cited as barriers to HBV screening among Asian American
populations.9 In this study, Treated participants were more
price sensitive than Treatment-naïve participants, probably
due to their exposure to the regular monthly outlay on CHB
treatment. Results of the cost-sensitivity exercise suggest
Table 3. Relative Impact of Product Attributes on Product Choice in the Discrete Choice Model, Overall and by Ethnicity and Treatment
Status













Long-term (5-year) risk of kidney damage 37.9 37.8 38.0 38.0 36.6 38.7
Monthly out-of-pocket cost 23.4 23.5 23.4 23.4 27.9 20.9
Long-term (5-year) risk of bone thinning 18.0 18.4 17.6 17.9 13.2 20.7
Long-term (5-year) efficacy 9.0 9.0 9.0 8.9 7.2 10.0
Time approved in US market 6.8 6.5 7.1 6.8 7.5 6.4
Level of use (no. of patients worldwide) 4.9 4.7 4.9 5.0 7.7 3.3
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that participants may be willing to sustain higher monthly
out-of-pocket costs than they currently report paying. The
influence of cost may be somewhat underestimated in this
study, as the sample included a relatively high proportion of
participants with relatively high socioeconomic class who
were already being followed in a clinic.
Long-term efficacy, time in market, and number of
patients worldwide were of relatively low importance to
the participants in this study. Education aimed at achieving
a better understanding of the importance of these aspects in
the treatment of a chronic disease such as CHB may help to
overcome the barriers presented by concerns over side
effects. There is a growing body of evidence, from clinical
and real-world studies, demonstrating that long-term treat-
ment with entecavir or tenofovir results in high rates of
virologic response, with minimal resistance rates, reversal
of liver disease, and favorable safety profiles.27,28
As with any study of this type, some limitations need to
be taken into consideration. The relative importance
assigned to the treatment attributes is clearly dependent on
the attributes and levels chosen for use in the model. Thus,
the risk of kidney disease may have been attributed a
particularly high relative importance, because the risk of
bone thinning was the only other potential adverse event
included. Information about the participants’ current level
of liver dysfunction and other comorbidities such as kidney
dysfunction was not recorded. This could have impacted
participants’ knowledge and choice of answers. However,
since possible comorbidities were neither selected for nor





























Figure 2. Likelihood of taking Product A at different monthly out-
of-pocket costs, among all participants, Treated participants, and
Treatment-naïve participants. *Percent of participants responding
‘definitely’ or ‘quite likely’ to the question “How likely would you
be to take this medication under each of the following monthly
costs (assuming the regimen takes at least 12 months)?” $300,
$350, $400, $450 price points were not measured; the dotted lines
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 I want to wait-and-see and avoid taking
medication for CHB aslong as possible†
If left untreated, CHB can lead
to serious liver damage
People with CHB should be treated
with prescription medication
There are effective prescription medications
to treat CHB
I am reluctant to take long term medication for
CHB because of my concerns about side-effects
I would take a CHB medication
if it weren’t too expensive†
Changing my lifestyle and diet





Figure 3. Treatment attitudes by treatment status. *Percent of
participants who completely or mostly agree with the statement.
†Questions only shown to Treatment-naïve participants.
"Base case" attributes for products A and B
Attributes A B
Long-term (5yr) risk of kidney damage 7% 15%
Long-term (5yr) risk of bone thinning <1% 10%
Long-term (5yr) efficacy 92% 71%
No. of patients worldwide 400,000 400,000
sry 4sry 6tekram SU ni emiT
Monthly out-of-pocket cost $50 $50






























































































































































5-year risk of kidney damage 
Figure 1. Discrete choice model sensitivity analysis showing the
impact on the relative preference for hypothetical products A (◊)
or B (▪) caused by changes in the levels of their individual
attributes. Base case attributes for each product are shown in the
table at the top of the figure. Each figure panel represents the
effect of changing the levels of one product attribute at a time,
while all other attributes for each product remain at base case
(indicated by the arrows on each panel).
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be in a minority. Sourcing of patients from in-person
methods and through multiple sources may have introduced
some bias, although the participant population did represent
a good balance of gender and socio-economic status.
Although levels of higher education and employment were
higher in the participant population, this remains represen-
tative of the Asian American population studied, since this
population has previously been shown to have a higher
level of education and employment compared with the
overall US population.29 Exclusion of patients unwilling to
take Western medicines may also have impacted on results;
for example, these individuals may have been less knowl-
edgeable about available treatments and/or more concerned
about side effects than the participants included in the study.
While the specific Asian populations included in the study
were chosen to represent those with the highest prevalence
of CHB, the inclusion of only Chinese, Korean, and
Vietnamese participants may limit the wider applicability
of the results to the Asian American population as a
whole. However, the lack of differences seen between
these populations, in terms of the results of the discrete
choice model, suggests that there may be little variation
between different ethnicities of the overall Asian
American population.
In 2011, the US Department of Health and Human
Services published an Action Plan for the Prevention, Care
and Treatment of Viral Hepatitis, detailing a comprehensive
strategic plan for viral hepatitis prevention and control.30
Two key goals were to improve viral hepatitis care and
treatment in primary care settings (recognizing that collab-
orations of primary-care providers and specialists result in
the best care for infected persons), and to decrease health
disparities by educating communities about the benefits of
viral hepatitis prevention and treatment. The results of our
study suggest that while most Asian Americans with CHB
are aware of the availability of effective antiviral treatment,
a considerable proportion (30 %) are not. Even with a high
level of awareness of available treatments, Asian American
individuals with CHB were reluctant to be treated because
of concerns about side effects. It is important that primary
care physicians working in Asian American communities
take this into consideration when discussing possible
treatments with their patients. Targeted education is needed
to emphasize the long-term safety and efficacy of available
antiviral therapies, highlighting the relatively low risk of
serious side effects compared with the life-threatening long-
term risks associated with progression of untreated CHB.
The role of the treating physician will be essential in
providing appropriate counseling and education about CHB
and the potential benefits of treatment.
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